Wine ingestion has no effect on lipid peroxidation products

Pharmacology

Volumn 75, Issue 3, 2005, Pages 152-156

  Ziegler, Sophie ^a   Kostner, Karam ^a   Thallinger, Christiane ^a   Bur, Andreas ^a   Brunner, Martin ^a   Wolzt, Michael ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coronary heart disease; Low density lipoprotein oxidation; Wine consumption

Indexed keywords

ALKADIENE; FATTY ACID; LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FERMENTATION; GRAPE; HUMAN; HUMAN EXPERIMENT; LIPID PEROXIDATION; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; RANDOMIZATION; REACTION TIME;

ADULT; ALKENES; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; WINE;

EID: 26644471743     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088291     Document Type: Article

References (29)

1. Doll R, Peto R, Hall E, Wheatley K, Gray R: Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ 1994;309:911-918.
2. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, Stampfer MS: Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991;338:464-468.
3. Groenbaek M, Dies A, Sorensen TIA, Becker U, Schnohr P, Jensen G: Mortality associated with moderate intakes of wine, beer or spirits. BMJ 1995;310:1165-1169.
4. Renaud S, De Logeril M: Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992;339:1523-1526.
5. Hollman PC, Van Trijp JM, De Vries K: Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 1997;114:139-140.
6. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M: Reduced progression of artherosclerosis in apolipoprotein E-deficient mice following consumption of red wine or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997;17:2744-2752.
7. Bertelli AA, Giovanni L, Giannessi D, Mitgliori M, Bernini W, Fregoni M, Bertelli A: Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
8. Flesch M, Schwarz A, Böhm M: Effects of red wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-1190.
9. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE: Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993;341:454-457.
10. Steinbrecher UP: Role of lipoprotein peroxidation in the pathogenesis of atherosclerosis. Clin Cardiol 1991;14:865-867.
11. Fuhrman B, Lavy A, Aviram M: Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-554.
12. de Vries JH, Hollman PC, van Amersfoort I, Olthof MR, Katan MB: Red wine is a poor source of bioavailable flavonols in men. J Nutr 2001;31:745-748.
13. Chajes V, Sattler W, Stultschnig M, Kostner G: Photometric evaluation of lipid peroxidation products in human plasma and copper oxidized low density lipoproteins: Correlation of different oxidation parameters. Atherosclerosis 1996;121:193-203.
14. Esterbauer H, Cheeseman KH: Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990;186:407-421.
15. Stolley P, Strom B: Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39:489-490.
16. Whitehead TP, Robinson D, Allaway S, Syms J, Hale A: Effect of red wine ingestion on the antioxidant capacity of serum. Clin Chem 1995;41:32-35.
17. Soleas GJ, Diamandis EP, Goldberg DM: Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 1997;11:287-313.
18. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH: Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-1834.
19. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
20. Manach C, Morand C, Crespy V, Deminge CH, Texier O, Regerat F, Remesy CH: Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 1998;426:331-336.
21. Ueno I, Nakano N, Hirono I: Metabolic fate of 14C-quercetin in the ACI rat. Jpn J Exp Med 1983;53:41-50.
22. O'Reilly JD, Sanders TA, Wiseman H: Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radic Res 2000;33:419-426.
23. Freese R, Alfthan G, Jauhiainen M, Basu S, Erlund I, Salminen I, Aro A, Mutanen M: High intakes of vegetables, berries, and apples combined with a high intake of linoleic or oleic acid only slightly affect markers of lipid peroxidation and lipoprotein metabolism in healthy subjects. Am J Clin Nutr 2002;76:950-960.
24. Lotito SB, Frei B: Relevance of apple polyphenols as antioxidants in human plasma: contrasting in vitro and in vivo effects. Free Radic Biol Med 2004;36:201-211.
25. Cherubini A, Beal MF, Frei B: Black tea increases the resistance of human plasma to lipid peroxidation in vitro, but not ex vivo. Free Radic Biol Med 1999;27:381-387.
26. Hayek T, Oiknine J, Brook JG, Aviram M: Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 1994;201:1567-1574.
27. Wolfram RM, Oguogho A, Efthimiou Y, Budinsky AC, Sinzinger H: Effect of black tea on (iso-)prostaglandins and platelet aggregation in healthy volunteers. Prostagland Leukot Essent Fatty Acids 2002;66:529-533.
28. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J, Aro A: Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000;56:545-553.
29. Mosca L, Rubenfire M, Tarshis T, Tsa A, Pearson T: Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 1997;80:825-839.